Celltrion establishes subsidiary in Vietnam

The company plans to obtain local sales approval for Remsima, Remsima SC, Truxima, and Herzuma in 2024

Celltrion establishes subsidiary in Vietnam
Jeong Min Nam 1
2024-09-30 16:04:15 peux@hankyung.com
Bio & Pharma

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam.

Celltrion plans to obtain approval to sell its major products, including Remsima, Remsima SC, Truxima, and Herzuma this year and supply these treatments across Vietnam.

Celltrion stated that it plans to expand its local workforce by more than double digits by the end of the year, hiring professionals for pharmaceutical sales and marketing.

The company will also build a communication network with Vietnam’s bidding agencies.

"Vietnam is a key pharmaceutical market within the ASEAN region, with an annual market size estimated at around 10 trillion won ($7.7 billion)," a Celltrion source added.

The company plans to complete product registration in major hospitals capable of prescribing biopharmaceuticals by the first half of next year.

Write to Jeong Min Nam at peux@hankyung.com
#Celltrion #Remsima #Remsima SC #Truxima #Herzuma

Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion's Herzuma Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ingredient: trastuzumab) won a bid from the Brazilian federal government, marking the fifth consecutive year of supply.As a result

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week on Sept. 11 Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract development and manufacturing organization (CDMO) market, led by Swis

Celltrion chairman announces venture into CDMO market

Celltrion chairman announces venture into CDMO market

Seo Jung-jin (center) speaks at Morgan Stanley 22nd Annual Global Healthcre Conference (Courtesy of Celltrion) South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the company said on Monday, citing its foun

Celltrion scraps merger with Celltrion Pharm

Celltrion scraps merger with Celltrion Pharm

Celltrion founder and Chairman Seo Jung-jin South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&D and local distribution affiliate, in the face of opposition from minority shareholders.They argued th

Costco sells Celltrion's Yuflyma Low WAC in US

Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now available for purchase at Costco in the US.According to Celltrion, Yuflyma was registered earlier this month under the Costco Membership Prescription P
(* comment hide *}